Author:
Platini F.,Cavalieri S.,Alfieri S.,Bergamini C.,Resteghini C.,Bottiglieri A.,Colombo E.,Mazzeo L.,Licitra L.,Paolini B.,Seregni E.,Locati L. D.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference38 articles.
1. N. Howlader, A. M. Noone, M. Krapcho, et al. SEER Cancer Statistics Review, 1975–2013. (National Cancer Institute, Bethesda, 2016) http://seer.cancer.gov/csr/1975_2013
2. M. Schlumberger, M. Tahara, L.J. Wirth et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372(7), 621–630 (2015)
3. M.S. Brose, C.M. Nutting, B. Jarzab et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomized, double-blind, phase 3 trial. Lancet 384(9940), 319–328 (2014)
4. R.I. Haddad, M. Schlumberger, L.J. Wirth et al. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine 56(1), 121–128 (2017)
5. A. Berdelou, I. Borget, Y. Godbert, et al. Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice. Thyroid; https://doi.org/10.1089/thy.2017.0205 (2017)
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献